ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Hepatitis B Virus Antisense Oligonucleotide AHB-137

Also written as “AHB-137”, “AHB-137 injection” and “AHB-137 (24 weeks)”.

Its studies are mostly in Hepatitis B, Chronic, led by 2 companies.

Drug pageHepatitis B Virus Antisense Oligonucleotide AHB-137: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 12, 202511 company-led studies, 8 open or runningNext primary completion: Dec 12, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ausper Biopharmaits history only86 open or runningphase 3since Aug 12, 2025Oct 11, 2023Dec 12, 2026phase 2 · NCT07137910
AusperBio Therapeutics32 open or runningphase 2since Jan 19, 2026Jan 20, 2023May 11, 2027phase 2 · NCT07654283

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AusperBio Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 20, 2023First study: phase 1 study in Hepatitis B, ChronicFirst studyNCT05717686 · 64 enrolled · United States, Hong Kong, New Zealand and more
  2. Jan 19, 2026Phase 2 study in Hepatitis B, ChronicPhase 2 reachedNCT07370207 · 84 planned · Australia, China, Japan and more
  3. May 28, 2026Phase 2 study in Hepatitis B, ChronicNCT07654283 · 70 planned · United States, Canada, France and more

Ahead

  1. May 11, 2027Primary completion: phase 2 study in Hepatitis B, ChronicNCT07654283
  2. Dec 31, 2028Primary completion: phase 2 study in Hepatitis B, ChronicNCT07370207

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 AusperBio Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07654283Hepatitis B, Chronic · United States, Canada, France and more2RecruitingMay 11, 202770
NCT07370207Hepatitis B, Chronic · Australia, China, Japan and more2RecruitingDec 31, 202884
NCT05717686Hepatitis B, Chronic · United States, Hong Kong, New Zealand and more1CompletedJan 7, 202564

How it is read

Names in the registry

  • “AHB-137”, 7 entries
  • “AHB-137 injection”, 3 entries
  • “AHB-137 (24 weeks)”, 1 entry
  • “AHB-137 (16 weeks)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.